A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

DENV-3 Controlled Human Infection Model

Interventions

DRUG: AV-1 100 mg
DRUG: AV-1 300 mg
DRUG: AV-1 900 mg
DRUG: Placebo

Sponsor

AbViro LLC